Brinzolamide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Brinzolamide
   1. Pharmacist Assessment Report
   2. Brinzolamide: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Brinzolamide: Known uses and market status in Canada

Summary

The TxGNN model produced candidates for Brinzolamide, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The one known use is supported by a licence in another country.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 3 of 3)
Number of DINs	3 (marketed: 3)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
primary hereditary glaucoma	licence in another country (approved indication: glaucoma)

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02238873	AZOPT		Valid
02435411	SIMBRINZA		Valid
02331624	AZARGA		Valid

Safety Considerations

• Drug Interactions: 32 potential interactions were identified in the interaction screening, but none has a severity level assigned. Examples include:
  • Proton pump inhibitors: pantoprazole, omeprazole, lansoprazole
  • Corticosteroids: prednisone, prednisolone, dexamethasone, triamcinolone
  • Anticoagulants and antiplatelets: warfarin, clopidogrel
  • Statins: simvastatin, rosuvastatin
  • Others: potassium chloride, pioglitazone, metoclopramide, famotidine, ranitidine

Systemic carbonic anhydrase inhibitor exposure raises safety concerns in children, which matters for the congenital and pediatric forms of hereditary glaucoma.

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---